Pfizer uses the Ion PGM platform for precision medicine in Chile

Last week, pharmaceutical giant Pfizer launched the Precision Medical Program Elite Center (CEPM) landing program in Chile.
's newly established center, Pfizer will focus on newer, more accurate and non-invasive cancer diagnoses, and in addition to Pfizer's $14 million investment in the project, Chile's Economic Development Agency (Corfo) will invest $7 million over four years.
Seymor Isil is a technical technology developer for the Precision Medicine Program, a phase of research that will use Ion PGM, a gene sequencing platform of Technologies, a subsidiary of Thermo Flies, which is already investing $3 million in the project.
Sylvia Varela, president of Pfizer's Latin American Oncology division, said in a statement that Pfizer's first phase of its study at the Elite Center for Precision Medicine Programs (CEPM), which currently has 1,800 to 2,100 patients a year in Chile, is based on molecular diagnostics from a new NGS platform.
marcela Angulo, technical director of the Chilean Economic Development Agency (Corfo), said: Chile is very capable of scientific research, Chile is not only committed to the basic knowledge into industry, but also to use the basic knowledge to improve people's lives. Through this strategic partnership, we will further promote the country's scientific research capabilities, level of development, innovation and Chile's position in the global genomic innovation and research sector. (Biological Exploration)